Skip to content

A multicenter, randomized, controlled trial for a novel vaginal microecologic therapy for the treatment of persistent cervical human papillomavirus infection at high risk

A multicenter, randomized, controlled trial for a novel vaginal microecologic therapy for the treatment of persistent cervical human papillomavirus infection at high risk

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003652
Enrollment
Unknown
Registered
2020-08-18
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV

Interventions

Sponsors

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 18 and 55, married or sexually active women; 2. Had been infected with HPV virus for more than one year 3. After sampling and examination in our hospital, the classification reported the presence of cervical HPV infection, and the syndrome differentiation of TRADITIONAL Chinese medicine belongs to the type of dampness and heat 4. signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Liquid base thin layer cytological examination (TCT) of highly squamous intraepithelial lesions and infiltrating carcinoma, or histopathological examination of CINII and above high-grade lesions; (2) Vaginal infections during the week prior to enrollment; (3) Those who were using other drugs to treat HPV infection or immunosuppressive drugs in the first three months before inclusion; (4) Women during pregnancy and lactation; (5) people who have mental diseases or diseases of important organs or metabolic diseases of the body; (6) Persons with infectious diseases, such as tuberculosis, hepatitis B, or venereal diseases; (7) For bad life habits or recent exposure to toxic substances, such as drugs, X-rays; (8) Therefore, other clinical trial investigators are being accepted.

Design outcomes

Primary

MeasureTime frame
HPV;

Countries

China

Contacts

Public ContactQian lin

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

qqqq19740@vip.sina.com+86 13816572075

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026